Potent and Persistent Antibody Response in COVID-19 Recovered Patients

Frontiers in Immunology

He Zhang¹  Wenjun Liu²  Ling Liu³  Wenguo Jiang⁴  Jing Li⁵  Xiaodong Tian⁶ 

[1] CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China;Institute of Microbiology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, China;Institutes of Physical Science and Information Technology, Anhui University, Hefei, China;Jining Center for Disease Control and Prevention, Shandong, China;Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China;School of Life Sciences, University of Science and Technology of China, Hefei, China;

关键词: COVID-19;    SARS-CoV-2;    antibody response;    recovered patients;    persistent;    potent;   

DOI  :  10.3389/fimmu.2021.659041

来源: DOAJ

【 摘 要 】

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms.

【 授权许可】

Unknown